Kenai Therapeutics Initiates First-in-Human Trial of RNDP-001 Neuron Replacement Therapy for Parkinson's Disease
核心洞察
Kenai Therapeutics has dosed the first patient in its Phase 1 REPLACE clinical trial of RNDP-001, an off-the-shelf neuron replacement cell therapy for moderate to moderate-severe idiopathic Parkinson's disease.
The therapy aims to replace lost dopamine-producing neurons through a precision neurosurgical procedure, moving beyond symptom management to address the root cause of the disease.
RNDP-001 has received FDA Fast Track designation and is built on a proprietary induced pluripotent stem cell platform, with initial safety and brain imaging data expected in 2026.
Kenai Therapeutics has achieved a significant milestone in Parkinson's disease treatment by dosing the first patient in its Phase 1 REPLACE clinical trial of RNDP-001, an innovative neuron replacement cell therapy. The San Diego-based clinical-stage biotechnology company announced this breakthrough on December 15, 2025, following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration.
Revolutionary Approach to Parkinson's Treatment
RNDP-001 represents a paradigm shift in Parkinson's disease therapy, designed as an off-the-shelf, allogeneic neuron replacement cell therapy that aims to restore motor function by replacing the dopamine-producing neurons lost to the disease. Unlike conventional treatments that focus on symptom management, this therapy targets the root cause of Parkinson's disease.
"While most Parkinson's disease treatments focus on symptom management, RNDP-001 aims to replace lost neurons, repair damaged neural circuits and restore motor function for patients with moderate to moderate-severe forms of the disease," said Nick Manusos, Chief Executive Officer of Kenai Therapeutics. "By moving beyond symptom control to address the root cause of disease, our goal is to offer patients a future with improved motor function and better overall quality of life."
FDA Fast Track Designation and Clinical Trial Design
The therapy has been granted Fast Track designation by the U.S. FDA in recognition of the urgent need for new therapies in Parkinson's disease. This designation is intended to accelerate development and review of RNDP-001, providing benefits including more frequent FDA interactions, eligibility for Accelerated Approval and Priority Review, and the option to submit a New Drug Application on a rolling basis.
The Phase 1 REPLACE study is an open-label, multi-center trial evaluating the safety and tolerability of RNDP-001, as well as brain imaging evidence of cell survival and engraftment, in adult patients with moderate to moderate-severe idiopathic Parkinson's disease. The therapy is delivered via a precision neurosurgical procedure into targeted areas of the brain, replacing dopamine-producing cells. The trial will enroll up to 12 patients with moderate to moderate-severe idiopathic Parkinson's disease, with initial safety, tolerability and brain imaging data from all 12 patients expected in 2026.
Advanced iPSC Platform Technology
RNDP-001 is built on Kenai's proprietary induced pluripotent stem cell (iPSC) platform that uses donor-derived, cryopreserved cells to enable an off-the-shelf product that can be scaled to address a growing global need. Through an exclusive and proprietary manufacturing partnership with FUJIFILM Cellular Dynamics (搜索), Inc., Kenai offers high-quality, reproducible production of dopamine progenitor cells for clinical use.
"Initiating this first-in-human trial represents the culmination of decades of foundational research in regenerative neuroscience," said Howard Federoff, M.D., Ph.D., Chief Medical Officer and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics. "What sets RNDP-001 apart is not just the depth of research behind it, but also its potential to intervene at the level of disease by replacing the dopaminergic neurons that are central to Parkinson's progression."
Company Pipeline and Future Prospects
Founded in 2022, Kenai Therapeutics is pioneering next generation approaches to cure neurological conditions by leveraging its proprietary, Nobel Prize-winning iPSC platform. The company is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Beyond RNDP-001, Kenai's additional programs target inherited and genetically driven subtypes of Parkinson's disease and other neurological conditions, with the goal of delivering long-lasting restoration of function.